Annette Tumolo - 11 Nov 2021 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Role
Executive Vice President
Signature
/s/ Annette Tumolo
Issuer symbol
BIO
Transactions as of
11 Nov 2021
Net transactions value
-$2,959,154
Form type
4
Filing time
15 Nov 2021, 09:55:24 UTC
Previous filing
09 Sep 2021
Next filing
22 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIO Bio-Rad A Common Stock Options Exercise $204,337 +613 +13% $333.34 5,206 11 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Options Exercise $166,670 +500 +9.6% $333.34 5,706 11 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Options Exercise $227,022 +433 +7.6% $524.30 6,139 11 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Sale $323,919 -433 -7.1% $748.08 5,706 11 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Sale $459,039 -613 -11% $748.84 5,093 11 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Sale $375,000 -500 -9.8% $750.00 4,593 11 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Options Exercise $95,592 +600 +13% $159.32 5,193 12 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Options Exercise $518,352 +2,400 +46% $215.98 7,593 12 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Options Exercise $587,070 +1,800 +24% $326.15 9,393 12 Nov 2021 Direct
transaction BIO Bio-Rad A Common Stock Sale $3,600,240 -4,800 -51% $750.05 4,593 12 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIO Non-Qualified Stock Option (right to buy) Options Exercise $0 -433 -25% $0.000000 1,300 11 Nov 2021 Bio-Rad A Common Stock 433 $524.30 Direct F2
transaction BIO Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,113 -40% $0.000000 1,671 11 Nov 2021 Bio-Rad A Common Stock 1,113 $333.34 Direct F3
transaction BIO Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,800 -60% $0.000000 1,200 12 Nov 2021 Bio-Rad A Common Stock 1,800 $326.15 Direct F4
transaction BIO Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,400 -80% $0.000000 600 12 Nov 2021 Bio-Rad A Common Stock 2,400 $215.98 Direct F5
transaction BIO Non-Qualified Stock Option (right to buy) Options Exercise $0 -600 -100% $0.000000* 0 12 Nov 2021 Bio-Rad A Common Stock 600 $159.32 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.00 to $750.61, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The option, representing a right to purchase a total of 1,733 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted.
F3 The option, representing a right to purchase a total of 2,784 shares, became exercisable in five equal annual installments beginning on September 3, 2020, which was the first anniversary of the date on which the option was granted.
F4 The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 4, 2019, which was the first anniversary of the date on which the option was granted.
F5 The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted.
F6 The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted.